Can-Fite BioPharma

Company Overview

Snapshot

Founded in September 1994 by Ilan Cohn, Can-Fite BioPharma operates with 11–50 employees. The company has raised a total of $113.45 million across 20 funding rounds from 2 investors. A significant milestone for the company was securing an Australian patent for its obesity drug Namodenoson in November 2024.

Business overview

Can-Fite BioPharma is an Israeli biopharmaceutical company focused on the discovery and clinical development of proprietary drug candidates. The company's core technology utilizes the Gi protein-associated A3 adenosine receptor (A3AR) as a therapeutic target, which is highly expressed in inflammatory, cancer, and other pathological cells. Can-Fite's compounds bind to A3AR to deregulate NF-kB and Wnt signal transduction pathways, producing anti-inflammatory and anticancer effects. Its pipeline includes drugs like Piclidenoson (CF101), Namodenoson (CF102), and CF602, addressing inflammatory, liver, metabolic, and rare genetic diseases, as well as oncology. The company serves global markets within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In September 2024, Can-Fite BioPharma announced a projected income of $325 million over the next 10 years following Vetbiolix's exercise of its option and licensing of Piclidenoson for veterinary osteoarthritis. This development signals strong commercial validation for Can-Fite's drug pipeline and indicates potential for significant long-term revenue generation from its intellectual property in the animal health market.

Company Intelligence Q&A

What was a key regulatory achievement for Can-Fite BioPharma in late 2024?

In November 2024, Can-Fite BioPharma secured an Australian patent for its anti-obesity drug, Namodenoson, marking a significant intellectual property expansion for the company.

What recent development occurred regarding Can-Fite's pancreatic cancer drug, Namodenoson?

In October 2024, the FDA granted Orphan Drug Designation to Can-Fite’s Namodenoson for pancreatic cancer, which can accelerate development and provide market exclusivity upon approval.

What was the outcome of the osteoarthritis clinical study in dogs treated with Piclidenoson?

In October 2024, Can-Fite BioPharma reported significant positive results from an osteoarthritis clinical study in dogs treated with Piclidenoson, indicating potential for its veterinary applications.

What was a notable clinical trial milestone for Can-Fite BioPharma in November 2024?

In November 2024, Can-Fite BioPharma achieved a milestone with the first patient dosing in its Pancreatic Cancer Phase IIa Clinical Trial for Namodenoson, advancing its oncology pipeline.

What strategic partnership was announced in September 2024?

In September 2024, Vetbiolix exercised its option and licensed Piclidenoson for veterinary osteoarthritis, projecting $325 million in income for Can-Fite BioPharma over the next 10 years.